REMARKS

The application is to be amended as set forth in an effort to conform the application more closely to U.S. practice. All amendments are made without prejudice or disclaimer. The amendments remove multiple dependencies from the claims.

If questions remain after consideration of the foregoing, the Office is kindly requested to contact applicants' attorney at the address or telephone number given herein.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: June 20, 2003

ACT/me

VERSION SHOWING CHANGES MADE

3. (Amended) The method of directing nucleic acid integration according to claim 1 [or 2], further comprising: inhibiting a component involved in nonhomologous recombination.

4. (Amended) The method according to claim 2 [or 3] wherein said component involved in nonhomologous recombination comprises *ku70*, *rad50*, *mre11*, *xrs2*, *lig4* or *sir4*.

5. (Amended) The method of directing integration of a nucleic acid of interest to a predetermined site according to [any one of claims 1 to 3] claim 1, wherein said nucleic acid of interest is essentially replacing a sequence within said eukaryote.

9. (Amended) The method of directing integration according to claim 7 [or 8] wherein said component involved in nonhomologous recombination comprises *rad50*, *mre11* or *xrs2*.

10. (Amended) The method according to [any one of claims 1 to 9] claim 1 wherein said eukaryote is selected from the group consisting of yeast, fungus, and an animal.

11. (Amended) The method according to [any one of claims 1 to 10] claim 1, wherein said nucleic acid of interest is delivered to a cell of said eukaryote by *Agrobacterium*.

12. (Amended) The method according to [any one of claims 1-11] claim 1 comprising transiently inhibiting integration via nonhomologous recombination.

15. (Amended) The method according to claim 13 [or 14] wherein said component involved in nonhomologous recombination comprises *ku70*, *rad50*, *mre11*, *xrs2*, *lig4* or *sir4*.

16. (Amended) The method according to [any one of the foregoing claims] claim 1

wherein said nucleic acid of interest comprises an inactive gene to replace an active gene.

17. (Amended) The method according to [any one of claims 1-14] claim 1, wherein said nucleic acid of interest comprises an active gene to replace an inactive gene.

18. (Amended) The method according to [any one of claims 1-14] claim 1, wherein said nucleic acid of interest encodes a therapeutic proteinaceous substance.

19. (Amended) The method according to [any one of claims 1-14] claim 1, wherein said nucleic acid of interest encodes a substance conferring resistance for an antibiotic substance to a cell.

20. (Amended) The method according to [any one of claims 1-14] claim 1, wherein said nucleic acid of interest confers a desired property to said eukaryote.

21. (Amended) The method according to [any one of the foregoing claims] claim 1 wherein said nucleic acid of interest is part of a gene delivery vehicle.

22. (Canceled herein).